Similarly, the LIBRETTO-531 trial has shown that selpercatinib use was associated with improved PFS and treatment failure-free survival versus MKIs in patients with RET-mutated MTC [10]. This evidence concerns the gene RET and medullary thyroid gland carcinoma.